retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly's Shows Staggering Weight Loss Results | Dr. Swahitagni Chakraborty posted on the topic Triple Agonism Based Therapies for

Executives from soda, candy companies and other makers of sweetener-containing products are worried about the impact of GLP-1 drugs that suppress appetites, but Carol Loeys of Circana, a market research firm, said that the primary driver in changing buying habits has been concern about costs

While research does indicate that certain mushrooms exhibit bioactive properties, they should be viewed as complementary rather than primary treatments

Semaglutide can increase your heart rate while you are at rest

A separate study following participants from the STEP 1 clinical trial found that weight, waist circumference and cardiometabolic risk factors largely returned toward baseline levels within 12 months of stopping the medication

Many trauma centers now specifically ask about GLP-1 agonists as part of their standard anesthesia assessment, but identification ensures the information reaches your team